Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug sequence aims to outsmart advanced breast cancer

NCT ID NCT07683754

Not yet recruiting Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine therapy, and two HER2-blocking antibodies. If the cancer progresses during maintenance, T-DXd can be given again. The goal is to maximize disease control, reduce side effects, and keep T-DXd effective for later use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, palbociclib, endocrine therapy
What this could lead to
If successful, this sequential strategy could improve long-term disease control and delay progression in advanced HER2+/HR+ breast cancer, while preserving T-DXd as a future treatment option.
What could go wrong
This is a Phase 3 trial, but results may not apply to all patients. Side effects from the drug combination, including lung or heart issues, are possible. The retreatment approach may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER HER2 POSITIVE HR POSITIVE METASTATIC BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.